Skip to main content
. 2017 Sep 1;7(4):157–166.

Table 2.

Final diagnoses after 124I-CLR1404 PET and method for determining final diagnoses

Patient no. Final Diagnosis after PET Change from initial diagnosis Method of diagnosis PET uptake MRI enhancement PET/Gad+MRI concordant/discordant
1 WHO IV glioma n/a Surgery Y Y Both
2 WHO III glioma Y Surgery Y Y Both
3 WHO II glioma N Surgery N N n/a
4 WHO IV glioma AND meningioma Y (glioma) Surgery AND MRI f/u Y AND Y Y AND Y Concordant AND concordant
N (meningioma)
5 Benign tx related change Y Clinical and MRI f/u N N n/a
6 WHO II glioma N Surgery Y N n/a
7 Benign tx related change Y Clinical and MRI f/u Y Y Concordant
8 Indeterminate* n/a Clinical and MRI f/u N N n/a
9 WHO IV glioma N Surgery Y Y Both
10 Benign tx related change Y Clinical and MRI f/u Y Y Concordant
11 WHO IV glioma N Clinical and MRI f/u Y Y Both
12 Benign tx related change Y Clinical and MRI f/u N Y n/a

Pathology determined final diagnoses for surgically treated patients and non-surgical patients had a final diagnosis based on 6 months of clinical and MRI follow-up. If MRI showed progression within 6 months, then diagnosis was confirmed as tumor recurrence. If MRI was stable or improving for 6 months, then diagnosis would be benign treatment related change.

*

Patient 8 had presumed tumor recurrence clinically and was treated with chemotherapy while MRI showed improvement. No pathology was available to confirm clinical findings.

Patient 11 had surgery at an outside hospital after PET and operative and pathological results were not available. By MRI, the patient had obvious progression of disease in the immediate post-operative period.

WHO is World Health Organization grading of brain tumors.